ANDA Approval Decline Continues, But Why?

 
• By Derrick Gingery

US FDA says COVID disruptions may be having an impact; complete response letters have also dropped significantly.

Down arrow with people watching
What does the decline in ANDA approvals and complete response letters issued say about the FDA generics program? • Source: Alamy

Full abbreviated new drug application approvals by the US Food and Drug Administration reached a new trough for fiscal year 2021 in June and now are on pace for the lowest annual total in four years.

The FDA reported 23 July that it granted 45 full ANDA approvals in June, which was one fewer than the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Biosimilars & Generics

US FTC Continues Effort To Eliminate Orange Book’s Improper Patent Listings

 
• By Urtė Fultinavičiūtė

In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which led to missed guidance publication deadlines.

Aurobindo, MSN Fail To Beat US Nuplazid Patent Expiring In August 2038

 
• By Dean Rudge

Acadia’s Nuplazid for hallucinations and delusions associated with Parkinson’s disease psychosis appears safe from generic competition until well into the next decade, following a favorable infringement and validity decision by a US district court.